Navigation Links
Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance
Date:4/25/2008

mal storage disorders and further strengthens our clinical pipeline. This Phase 1-2 product will reinforce our strategic position in this orphan indication and will potentially allow us to bring an MLD treatment to patients two years earlier than anticipated.

At the end of March, we announced a co-promotion agreement with TAP Pharmaceutical Products Inc. for LIALDA, adding more than 500 additional sales representatives from TAP to increase the reach and frequency of our sales calls. Shire's GI team has made LIALDA the fastest growing brand of mesalamine and with the TAP collaboration we will be able to reach more GI specialists as well as primary care providers.

We are reaffirming our previous financial guidance for 2008 and continue to expect positive revenue growth through 2010."

Product Highlights

VYVANSE(TM) - Attention Deficit and Hyperactivity Disorder ("ADHD")

- By April 11, 2008 VYVANSE had achieved a US ADHD market share of 6.9% based on weekly prescription volumes, up from 5.2% as at December 31, 2007. In February 2008, VYVANSE achieved its one millionth prescription.

- By April 1, 2008 Shire had agreements with seven of its top ten managed care organizations for VYVANSE.

- Sales for the three months to March 31, 2008 were $54.4 million (2007: $nil).

- With the addition of VYVANSE, Shire's average share of the US ADHD market for the three months to March 31, 2008 was 31.8% (2007: 28.5%). Shire has the leading portfolio of products in the US ADHD market.

DAYTRANA(TM) - ADHD

- Sales for the three months to March 31, 2008 were $20.3 million (2007: $11.9 million).

- On January 9, 2008, the US Food and Drug Administration ("FDA") issued a Warning Letter to Noven Pharmaceuticals Inc. ("Noven"), which primarily related to Noven's manufacture of DAYTRANA. Further regulatory action could result if the FDA's concerns are not satisfied fully. Noven submitted a response to the FDA on January
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
3. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
4. Sigma-Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO/IEC 17025 and ISO Guide 34
5. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
6. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
7. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
8. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
9. ITSSD: Russia Can Secure Greatest Biotech Market Advances Following US, Not EU Innovation Model
10. Optherion, Inc. Completes $37 Million Start Up Financing
11. Actress Aida Turturro Tells Americans to Start Now to Talk With Their Healthcare Provider About Taking Control of Their Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... OSLO, December 11 Algeta ASA ... the first clinical center in the,US, the ... randomizing patients,in the phase III clinical study ... as hormone-refractory) prostate cancer,(CRPC) that has metastasized ... The ALSYMPCA (ALpharadin in SYMptomatic Prostate ...
(Date:12/11/2009)... CAMBRIDGE, Mass., Dec. 11 Gwathmey, ... company specializing in cancer, staph aureus, and cardiovascular ... Pre-clinical Services announced today that Rosalie Dunn, Ph.D., ... Dr. Dunn has over 28 years of experience ... Prior to joining Gwathmey, Dr. Dunn managed ...
(Date:12/11/2009)... 11, 2009 -- Esco announces the opening of a NEW 2nd ... a technical service, training and logistics center to support Esco,s growth ... Product Introductions (NPI) for temperature-controlled laboratory equipment. , ... ... of a NEW 2nd North American facility in Marietta, OH. The ...
(Date:12/10/2009)... Microban International, Ltd., the global ... partnered with Sharp Imaging and Information Company ... to incorporate it,s third generation silver-based antimicrobial ... into the calculator keys during manufacture, Microban ... of damaging bacteria on the keys. ...
Breaking Biology Technology:Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4Rosalie Dunn, Ph.D., Joins Gwathmey, Inc. as Chief Executive Officer 2Microban Signs Exclusive Agreement with Sharp Electronics to Launch Calculators with New Microban(R) 3G Silver(TM) Antimicrobial Technology 2
... Novavax, Inc.,(Nasdaq: NVAX ) and the ... from a preclinical study of a Respiratory Syncytial ... worldwide rights from the, University of Massachusetts Medical ... commercialization of Paramyxovirus vaccines incorporating,certain Virus-Like-Particles ("VLPs"). ...
... NOVATO, Calif., Dec. 9 BioMarin Pharmaceutical,Inc. ... that its partner Merck Serono, a division,of ... approval for,Kuvan(R) (sapropterin dihydrochloride) for the treatment ... deficient patients,from the European Commission. Merck ...
... favorable results from a Phase 1 vehicle-controlled study of ... during urological surgery. , , ... patients undergoing endoscopic removal of urinary stones, and was ... the drug product. The pharmacokinetic data from this study ...
Other Biology Technology:NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate 2NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate 3NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate 4Kuvan Receives Marketing Approval in the European Union 2Kuvan Receives Marketing Approval in the European Union 3Kuvan Receives Marketing Approval in the European Union 4Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery 2
(Date:12/14/2009)... that could help wean the nation from oil, would ... gasoline, especially in winter, according to a new study ... both gasoline and E85, a blend of gasoline and ... warm sunny weather than during the cold weather and ... to ozone formation. But E85 produces different byproducts of ...
(Date:12/14/2009)... A team of researchers from the Astrobiology Centre (INTA-CSIC) ... considered essential to the formation of the most basic ... blue. In order to carry out this study, published ... scientists recreated the chemical conditions of the early Earth. ... dissolved in ammoniac solutions it produces hydrogen cyanide, a ...
(Date:12/13/2009)... help to engineer plants that take advantage of elevated ... could help to engineer crops that take advantage of ... dioxide they need for photosynthesis through microscopic breathing pores ... of the gas gained, they lose hundreds of water ... to save water when CO 2 is abundant, ...
Breaking Biology News(10 mins):Ethanol-powered vehicles generate more ozone than gas-powered ones 2Ethanol-powered vehicles generate more ozone than gas-powered ones 3Prussian blue linked to the origin of life 2Newly identified enzymes help plants sense elevated CO2 and could lead to water-wise crops 2Newly identified enzymes help plants sense elevated CO2 and could lead to water-wise crops 3Valley Riding Will Host Horse Festival in the Cleveland Metroparks on Sunday August 23 from 11 AM to 4 PM 54833 1Valley Riding Will Host Horse Festival in the Cleveland Metroparks on Sunday August 23 from 11 AM to 4 PM 54833 2Sonic Innovations Awarded Contract From U S Veterans Administration 54829 1Sonic Innovations Awarded Contract From U S Veterans Administration 54829 2Sonic Innovations Awarded Contract From U S Veterans Administration 54829 3Analysis of Biofuels Indirect Land Use Effects Finds the Science Lacking 3A Too Diffuse and Subject To Too Many Arbitrary Assumptions To Be Useful for 13624 1Analysis of Biofuels Indirect Land Use Effects Finds the Science Lacking 3A Too Diffuse and Subject To Too Many Arbitrary Assumptions To Be Useful for 13624 2Analysis of Biofuels Indirect Land Use Effects Finds the Science Lacking 3A Too Diffuse and Subject To Too Many Arbitrary Assumptions To Be Useful for 13624 3
... the Faculty of Life Sciences (LIFE) at the University of ... than milk chocolate, lessening our craving for sweet, salty and ... an efficient way to keep your weight down over Christmas. ... it is healthier to eat dark chocolate, but now scientists ...
... additives and refined sweeteners in commercial salad dressings, said ... on the positive health effects of honey, we experimented ... a U of I associate professor of food chemistry. ... quality of the salad dressings for up to nine ...
... Jason Goldstein checks his lobster traps in New ... for tasty crustaceans to sell. Instead, the University of ... transmitters and tracking their migrations year-round. , ... and into Great Bay throughout the past two years. ...
Other Biology News:The dark chocolate version of Father Christmas is most filling 2Honey adds health benefits, is natural preservative and sweetener in salad dressings 2UNH researchers track lobster migrations to improve population estimates 2UNH researchers track lobster migrations to improve population estimates 3
... (Klenow) Fragment, Exonuclease Minus, is a DNA-dependent ... and the 3´→5´ exonuclease activities present in ... It is used for random primer labeling ... Klenow Fragment, Exonuclease Minus, will leave a ...
Goat polyclonal to Duffy / FY / DARC...
... The Centra-CL5R multi-purpose centrifuge offers both ... large assortment of rotor options, making ... laboratory applications., Maximum Versatility , ... xg) angle rotors or high-volume (4 x ...
... The H2OBIT™ is a fully licensed, high throughput, ... processing of up to 24 microplates. This equates ... plates. A robotic arm rapidly transfers ... resulting in temperature ramping times that are considerably ...
Biology Products: